Three-year outcomes of two phase II studies of adjuvant chemotherapy with S-1 plus oxaliplatin or capecitabine plus oxaliplatin in patients with stage III gastric cancer after D2 gastrectomy.

作者
Yoshiaki Nakamura,Takeharu Yamanaka,Keisho Chìn,Haruhiko Cho,Hitoshi Katai,Masanori Terashima,Seiji Ito,Motohiro Hirao,Kazuhiro Yoshida,Eiji Oki,Mitsuru Sasako,Yasunori Emi,Hideaki Bando,Yoshiyuki Kawashima,Tetsu Fukunaga,Masahiro Gotoh,Takako Ishibashi,Kohei Shitara
出处
期刊:Journal of Clinical Oncology [Lippincott Williams & Wilkins]
卷期号:36 (4_suppl): 94-94 被引量:1
标识
DOI:10.1200/jco.2018.36.4_suppl.94
摘要

94 Background: Two phase II trials of oxaliplatin-based adjuvant chemotherapy for patients (pts) with gastric cancer (GC) after D2 gastrectomy have been conducted in Japan; the J-CLASSIC study of capecitabine plus oxaliplatin (CAPOX) and the SOXaGC study of S-1 plus oxaliplatin (SOX). In the current study, we evaluated survival outcomes of the two trials. Methods: The J-CLASSIC, enrolling stage II and III pts from 12 centers between July 2012 and July 2013, evaluated eight cycles of CAPOX. The SOXaGC, enrolling stage III pts from 11 centers between July 2013 and February 2014, evaluated seven cycles of SOX after one cycle of S-1 monotherapy. The two studies were conducted sequentially and most centers (9 centers) participated in both trials. In this pooled analysis, we updated relapse-free survival (RFS) and overall survival (OS) information. The median follow-up time was 49 months in the J-CLASSIC and 39 months in the SOXaGC. Results: Fifty-nine stage III pts treated with CAPOX and 62 stage III pts treated with SOX were analyzed. The 3-year RFS and OS rates of SOX were 70.9% (57.8-80.5%) and 75.7% (63.0-84.6%), respectively, whereas the 3-year RFS and OS rates of CAPOX were 67.8% (54.3-78.1%) and 79.3% (66.5-87.7%), respectively. The hazard ratio (HR) of SOX in comparison to CAPOX was 0.925 (0.498-1.720) for RFS, suggesting the efficacy of the two treatments was similar. Trend of a different efficacy was observed in some particular subgroups; the HR for RFS was 1.732 (0.506-5.927) in the intestinal type and 0.735 (0.353-1.528) in the diffuse type, while that was 2.008 (0.447-9.016) in stage IIIA, 0.872 (0.266-2.857) in stage IIIB, and 0.597 (0.258-1.383) in stage IIIC. Conclusions: This is the first report of survival follow-up in Japanese GC pts with oxaliplatin-based adjuvant chemotherapy, which suggests comparable outcomes in both treatments for stage III GC. Different trend in the treatment effect by histologic type or stage warrants further evaluation in a larger cohort. Clinical trial information: UMIN000026883.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
yan完成签到,获得积分10
刚刚
欢喜新梅完成签到,获得积分10
刚刚
锈了的xuebxuebi雪碧完成签到,获得积分10
刚刚
刚刚
若冰完成签到,获得积分10
刚刚
WUXIN完成签到,获得积分10
刚刚
1秒前
greenren完成签到,获得积分10
1秒前
唐糖完成签到,获得积分10
1秒前
脑洞疼的应助被小繁采纳,获得10
1秒前
连续流工艺技术完成签到,获得积分10
1秒前
欢呼妙菱完成签到,获得积分10
1秒前
香蕉觅云的应助被忧郁觅山采纳,获得10
1秒前
zhongjr_hz完成签到,获得积分10
1秒前
张玖完成签到,获得积分10
2秒前
3秒前
屹舟完成签到,获得积分10
3秒前
Cytheria完成签到,获得积分10
3秒前
聪明戒指发布了新的文献求助10
3秒前
小二郎的应助被he采纳,获得10
3秒前
白璇完成签到,获得积分10
3秒前
ding的应助被明云采纳,获得10
4秒前
喜悦白玉发布了新的文献求助10
4秒前
小果儿完成签到,获得积分10
4秒前
严采波完成签到,获得积分10
4秒前
Hh完成签到,获得积分10
4秒前
4秒前
傲娇的沁完成签到,获得积分10
5秒前
求助文献发布了新的文献求助10
5秒前
dasfsdf完成签到,获得积分0
5秒前
充电宝的应助被369ninja采纳,获得10
6秒前
Windsyang完成签到,获得积分10
6秒前
ljy完成签到,获得积分10
6秒前
好运来完成签到,获得积分10
7秒前
able0812发布了新的文献求助10
7秒前
7秒前
Lxy完成签到 ,获得积分10
7秒前
天想月完成签到,获得积分10
7秒前
7秒前
乐空思的应助被文章多多采纳,获得30
8秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
Social Psychology in the Real World 600
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8180189
求助须知:如何正确求助?哪些是违规求助? 9570320
关于积分的说明 21810161
捐赠科研通 7776320
什么是DOI,文献DOI怎么找? 3433267
关于科研通互助平台的介绍 2557483
邀请新用户注册赠送积分活动 2479039